<DOC>
	<DOCNO>NCT01634282</DOCNO>
	<brief_summary>The purpose clinical study evaluate safety OPC-262 ( 2.5 mg 5 mg ) patient type 2 diabetes long-term administration orally 52 week evaluate efficacy OPC-262</brief_summary>
	<brief_title>Along-term Study OPC-262 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients complete Study 26209001 ( namely , patient visit hospital visit Week 24ï¼‰ Patients capable give informed consent prior participate clinical study Patients able take contraceptive measure avoid pregnancy patient patient 's partner entire study period 4 week study ( end postobservation period ) Patients withdraw Study 26209001 Patients experience serious adverse event relationship study drug deny Study 26209001 Patients experience serious adverse event relationship study drug deny Study 26209001 whose symptom still emerge time initiation study Patients meet exclusion criterion Study 26209001 study period Study 26209001 Female patient wish become pregnant study period Study 26209002 within 4 week study Patients otherwise judged investigator subinvestigator inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>